724
National Cancer Institute (NCI) , 369–370,
609, 613
National Human Genome Research Institute
(NHGRI) , 14, 611, 639, 683
National Institute of General Medical Sciences
(NIGMS) , 27, 611–613
National Institute of Health (NIH)
caBIG , 609–610
collaboration with FDA , 610
funding , 612–613
GTR , 610–611
research tools , 610
Roadmap Initiative for Medical
Research , 609
National Institute of Standards and
Technology (NIST) , 613
Natural killer (NK) cells , 551, 552
Near-infrared fl uorescence (NIRF) imaging , 94
Nephrogenic diabetes insipidus , 162, 163
Nephrotoxicity , 125, 167
Neuroblastomas , 289
Neurological disorders
Alzheimer’s disease ( see Alzheimer’s
disease (AD))
ataxias , 455–456
chronic fatigue syndrome , 455
diagnosis-guided therapies , 417
epilepsy ( see Epilepsy)
future prospects , 456
Huntington’s disease , 424–425
migraine , 435–437
multiple sclerosis ( see Multiple
sclerosis (MS))
neurogenomics
applications , 410–411
epigenomics/epigenetics , 412–413
healthcare, impact on , 412
neurometabolomics , 417
neuroproteomics
blood-brain barrier , 414
CNS proteomics , 414
CSF examination , 414, 415
myelin basic protein concentrations , 416
neuronal regeneration and
degeneration , 414
neuron-specifi c enolase , 415–416
neuropharmacology, role of , 416
neuroprotection , 413
neurotransmitters , 413
NMDAR , 413
S-100 protein , 414–415
transthyretin , 416
pain management
on brain imaging , 452
genetic factors , 446–447
genetic mutations , 448
mechanisms , 451
pharmacogenetics/pharmacogenomics ,
448–450
preoperative testing , 451
Parkinson disease , 421–424
personalized biological therapies , 417–418
sleep disorders , 454–455
stroke , 437–440
traumatic brain injury , 454
Neuronal nitric oxide synthase (nNOS) ,
484, 535
Neurotoxicity , 116, 167
NewGene Inc , 298
New York Genome Center (NYGC) , 279, 622
Next-generation sequencing (NGS) , 42–43,
157, 262–263
breast cancer genetic test , 298
leukemia, personalized therapy of , 327
oncology test system , 203
Neyman-Pearson approach , 95, 593
NGS. See Next-generation sequencing (NGS)
NIGMS. See National Institute of General
Medical Sciences (NIGMS)
NIH. See National Institute of Health (NIH)
Non-communicable diseases (NCDs) , 28, 158
Non-genomic factors
circadian rhythms , 180–181
cytomics , 184–185
epigenomics , 183–184
intestinal microfl ora
human genome , 182–183
metabolic interactions, host , 183
nanobiotechnology , 185–187
Non-Hodgkin lymphoma (NHL) , 255
Non-pharmacological therapies
acupuncture , 577–578
HBO therapy , 578–579
nutrition ( see Nutrition)
physical exercise , 584–585
surgery , 585–586
Non-small cell lung cancer (NSCLC)
chemotherapy, effi cacy of , 229–230
crizotinib , 347
FDG-PET , 215
KIF5B/RET fusion oncogene , 352
platinum-based therapy , 352
Nucleoside reverse transcriptase inhibitors
(NRTIs) , 393
Nutraceuticals , 579
Nutrition , 579–580
metabolomics , 176
nutrigenomicsIndex